The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.

The present invention provides a subcutaneous injection product for cattle for inducing superovulation characterized by comprising aluminum hydroxide gel and an efficient amount of a gonadotropin, wherein the concentration of the aluminum hydroxide is, in terms of the amount of aluminum, higher than or equal to 0.2 mg/mL and lower than 1.0 mg/mL, which is a subcutaneous injection product that is useful for producing good calves and that can induce superovulation in a cow by a single administration. The present invention also provides a method for producing good calves undergoing steps of subcutaneously injecting the aforementioned injection product into a cow to thereby induce superovulation, inducing estrus in the cow, conducting artificial insemination, and then collecting fertilized eggs.

The present invention provides a subcutaneous injection product for cattle for inducing superovulation characterized by comprising aluminum hydroxide gel and an efficient amount of a gonadotropin, wherein the concentration of the aluminum hydroxide is, in terms of the amount of aluminum, higher than or equal to 0.2 mg/mL and lower than 1.0 mg/mL, which is a subcutaneous injection product that is useful for producing good calves and that can induce superovulation in a cow by a single administration. The present invention also provides a method for producing good calves undergoing steps of subcutaneously injecting the aforementioned injection product into a cow to thereby induce superovulation, inducing estrus in the cow, conducting artificial insemination, and then collecting fertilized eggs.

The present invert on relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).

Methods and compositions for synchronizing the time of insemination in gilts are provided. More particularly, methods and compositions for synchronizing the time of insemination in gilts using a gonadotropin-releasing hormone and a hormone for synchronizing estrus are provided.

Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.

A novel process for the preparation of a long acting injectable composition based on biodegradable poly(D,L-lactide-co-glycolide) microspheres comprising peptide active pharmaceutical ingredients.

[Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid.

[Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid.